Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$66.83 USD
-0.43 (-0.64%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $66.84 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Edwards Lifesciences Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 6,005 | 5,382 | 5,233 | 4,386 | 4,348 |
Cost Of Goods | 1,380 | 1,080 | 1,249 | 1,081 | 1,114 |
Gross Profit | 4,625 | 4,302 | 3,984 | 3,306 | 3,234 |
Selling & Adminstrative & Depr. & Amort Expenses | 3,091 | 2,554 | 2,293 | 2,408 | 2,087 |
Income After Depreciation & Amortization | 1,534 | 1,749 | 1,690 | 898 | 1,147 |
Non-Operating Income | 82 | 38 | 30 | 35 | 40 |
Interest Expense | 18 | 19 | 18 | 16 | 21 |
Pretax Income | 1,598 | 1,767 | 1,702 | 917 | 1,167 |
Income Taxes | 199 | 246 | 199 | 93 | 120 |
Minority Interest | -3 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1,399 | 1,522 | 1,503 | 823 | 1,047 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 1,402 | 1,522 | 1,503 | 823 | 1,047 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 1,679 | 1,888 | 1,825 | 1,005 | 1,236 |
Depreciation & Amortization (Cash Flow) | 145 | 140 | 135 | 107 | 89 |
Income After Depreciation & Amortization | 1,534 | 1,749 | 1,690 | 898 | 1,147 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 609.40 | 624.20 | 631.20 | 631.90 | 636.60 |
Diluted EPS Before Non-Recurring Items | 2.51 | 2.48 | 2.22 | 1.86 | 1.86 |
Diluted Net EPS (GAAP) | 2.30 | 2.44 | 2.38 | 1.30 | 1.64 |
Fiscal Year end for Edwards Lifesciences Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1,385.90 | 1,598.20 | 1,534.10 | 1,480.90 | 1,530.20 |
Cost Of Goods | 285.30 | 385.60 | 356.90 | 350.40 | 343.00 |
Gross Profit | 1,100.60 | 1,212.60 | 1,177.20 | 1,130.50 | 1,187.20 |
SG&A, R&D, and Dept/Amort Expenses | 731.50 | 825.10 | 777.10 | 712.10 | 860.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 369.10 | 387.50 | 400.10 | 418.40 | 327.20 |
Non-Operating Income | 17.50 | 21.90 | 39.20 | 20.90 | 11.30 |
Interest Expense | 0.00 | 0.00 | 17.60 | 0.00 | 0.00 |
Pretax Income | 386.60 | 409.40 | 421.70 | 439.30 | 338.50 |
Income Taxes | 20.20 | 58.40 | 52.00 | 55.60 | 33.00 |
Minority Interest | -1.30 | -0.90 | -0.20 | -1.20 | -1.60 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 366.40 | 351.00 | 369.70 | 383.70 | 305.50 |
Extras & Discontinued Operations | -1.40 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 366.30 | 351.90 | 369.90 | 384.90 | 307.10 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 604.30 | 604.10 | 606.90 | 609.50 | 610.30 |
Diluted EPS Before Non-Recurring Items | 0.70 | 0.66 | 0.64 | 0.59 | 0.66 |
Diluted Net EPS (GAAP) | 0.61 | 0.58 | 0.61 | 0.63 | 0.50 |